Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan
This article was originally published in The Pink Sheet Daily
Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.
You may also be interested in...
High court rules Federal Circuit should have granted deference to district court’s decision on meaning of a patent claim for a multiple sclerosis drug.
High court rules Federal Circuit should have granted deference to district court’s decision on meaning of Copaxone patent claim; Federal Circuit must now reconsider its finding that the patent is invalid.
Justice Breyer seems to side with Teva’s position that Federal Circuit should have deferred to district court’s finding on meaning of patent term central to Copaxone’s manufacturing process, but other justices appear skeptical.